Asosiy kontentga oʻtish
Boshqa

DB07 Feasibility of Implementing DEKODE Surveillance Registry in Different Healthcare Settings: Pilot Data from Uzbekistan, Serbia and India

K PersadSandwell and West Birmingham NHS Hospitals Trust , Birmingham ,A MantaDepartment of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham , Birmingham ,A AlievaCentre of Endocrinology , Tashkent ,A A KojanazarovCentre of Endocrinology , Tashkent ,K SaravinovskaClinic of Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia , Belgrade ,M MarinkovicClinical Hospital Centre Zemun , Belgrade ,Z GluvicZemun HospitalS SinghJSS Medical College , Mysuru ,A BiswajitJSS Medical College , Mysuru ,V GudivakaJSS Medical College , Mysuru ,N T MathewJSS Medical College , Mysuru ,P KempegowdaQueen Elizabeth Hospital Birmingham , Birmingham ,
2026en
ABI

Annotatsiya

Abstract Introduction and purpose The Digital Evaluation of Ketosis and Other Diabetes Emergencies (DEKODE) is a cloud-based auditing tool developed within the NHS, UK to provide performance feedback on care for diabetes-related ketoacidosis (DKA) and to reduce data-collection burden. We report DEKODE's first international implementation across two non-UK healthcare systems. Methods This prospective feasibility study was conducted from September 2025 to May 2026 in Uzbekistan, India, and Serbia. DKA episodes were identified using standard biochemical criteria (glucose ≥11 mmol/L, ketones ≥3 mmol/L, pH ≤7.3 or bicarbonate ≤15 mmol/L). Data collected included demographics, diabetes type, Charlson Comorbidity Index (CCI), DKA duration, length of stay (LOS), and metabolic complications. Results are reported descriptively as medians (IQR) or proportions. Results At all centres, local teams were established and trained within the DEKODE framework without requiring significant modification to the core data collection protocol. The Uzbekistan centre reported 146 episodes from 2021 to 2025: median DKA duration 14.5 hours (IQR 11–20), median LOS 1 day (IQR 1–2). The India centre reported 115 episodes from 2021 to 2025: median DKA duration 48 hours (IQR 36–72), median LOS 5 days (IQR 3–7). Serbia reported 53 episodes from 2022 to 2025: median LOS 9 days (IQR 6.3–12), DKA duration 46 hours (IQR 10–48). The frequency of hypokalaemia, hyperkalaemia, hypoglycaemia, and reasons for delayed discharge, where applicable, were also captured within the DEKODE model. Conclusion DEKODE was successfully implemented across diverse international settings, enabling standardised data collection. These findings support its scalability as a global DKA surveillance platform.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba